Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pharnext
Pharnext Appoints Antoine Gravelle as General Counsel
July 05, 2022
From
Pharnext
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
June 28, 2022
From
Pharnext
Via
AccessWire
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
June 20, 2022
From
Pharnext
Via
AccessWire
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
June 08, 2022
From
Pharnext
Via
AccessWire
Topics
Bonds
Exposures
Debt Markets
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
May 30, 2022
From
Pharnext
Via
AccessWire
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
May 05, 2022
From
Pharnext
Via
AccessWire
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
March 30, 2022
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharnext Appoints Valérie Worrall as Chief Financial Officer
February 15, 2022
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
December 23, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
December 22, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Bonds
Exposures
Artificial Intelligence
Debt Markets
Pharnext Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Research & Development
November 22, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Pharnext Confirms Details for 2021 Hybrid Research & Development Day
October 21, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharnext Strengthens its Management Team with Three Key Appointments to Support Ongoing Development of PXT3003 Toward Approval and Commercialization
October 19, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases
October 18, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Pharnext Reports First Half 2021 Financial Results
October 14, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Bonds
Exposures
Artificial Intelligence
Debt Markets
Pharnext to Host 2021 Hybrid Research & Development Day
October 06, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Piers Morgan Joins Pharnext's Board of Directors
July 15, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
July 12, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharnext: Shareholder Letter
June 21, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Bonds
Exposures
Artificial Intelligence
COVID-19
Debt Markets
Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study
June 07, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Bonds
Exposures
Artificial Intelligence
Debt Markets
Pharnext Reports Financial Results for Year-End 2020
April 27, 2021
From
Pharnext
Via
AccessWire
Topics
Artificial Intelligence
Bonds
Exposures
Artificial Intelligence
Debt Markets
Product Safety
Tickers
PNEXF
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.